PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsEnoblituzumab
Enoblituzumab
Enoblituzumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against CD276 antigen.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
2-oak mix, red/white pollen 3-oak mix, black/blackjack/post pollen 3-ragweed mix, giant/short/western pollen 4-pine mix, austrian/loblolly/scotch/w...Biologic Licensing Application2011-03-11
ad incontinence supportC2002632025-03-07
avance incontinence careC2002632024-05-11
bioelements, inc.OTC monograph not final2012-01-17
ca-rezz - long term care - incontinent cleanserC2002632024-12-26
ca-rezz - norisc - incontinent washC2002632024-12-27
center-al - acacia longifolia pollen center-al - acer negundo pollen center-al - acer saccharum pollen center-al - agrostis gigantea center-al - al...Biologic Licensing Application2009-06-12
chain drug marketing association, inc.C2002632024-05-21
crooked creek distillery inc hand sanitizerOTC monograph not final2020-03-25
cvs pharmacy,inc.C2002632024-08-16
Show 58 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
11 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———321—21954
NeoplasmsD009369—C809711216
OsteoarthritisD010003EFO_0002506M15-M1921—2712
ObesityD009765EFO_0001073E66.9———11011
Atrial fibrillationD001281EFO_0000275I48.0—211711
Wounds and injuriesD014947—T14.832—159
Knee osteoarthritisD020370EFO_0004616M17—1—258
Spinal cord injuriesD013119EFO_1001919—11—168
GlaucomaD005901EFO_0000516H40—12137
Postoperative painD010149—G89.18———156
Show 56 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CarcinomaD002277—C80.0462—313
SyndromeD013577————4—913
Lung neoplasmsD008175—C34.90523—110
Coronary artery diseaseD003324—I25.1——2—79
Non-small-cell lung carcinomaD002289——522——8
InfectionsD007239EFO_0000544—231—37
Coronary diseaseD003327————2—46
Myocardial ischemiaD017202EFO_1001375I20-I25——1—56
Prostatic neoplasmsD011471—C61351——6
Cardiovascular diseasesD002318EFO_0000319I98121—36
Show 73 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypertensionD006973EFO_0000537I1043——712
Breast neoplasmsD001943EFO_0003869C5023——710
StrokeD020521EFO_0000712I63.9—1——89
Covid-19D000086382—U07.111——78
DepressionD003863—F33.931——37
MelanomaD008545——51——16
Renal cell carcinomaD002292EFO_0000376—32——15
KeratoconusD007640EFO_0004223H18.6—1——45
Depressive disorderD003866EFO_1002014F32.A—1——45
Hiv infectionsD015658EFO_0000764B2041———4
Show 72 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MalnutritionD044342EFO_0008572E40-E4613———215
HivD006678—O98.71———45
Acne vulgarisD000152EFO_0003894L703———14
HemorrhageD006470MP_0001914R581———34
AnxietyD001007EFO_0005230F41.11———34
Type 2 diabetes mellitusD003924EFO_0001360E111———34
Colonic neoplasmsD003110—C181———23
Rheumatoid arthritisD001172EFO_0000685M06.91———23
ThrombosisD013927——1———23
MalariaD008288EFO_0001068B541———12
Show 49 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CataractD002386EFO_0001059H26.9————66
Cognitive dysfunctionD060825—G31.84————66
Heart diseasesD006331EFO_0003777I51.9————55
Respiratory distress syndromeD012128EFO_1000637J80————44
Newborn respiratory distress syndromeD012127—P22————44
Aortic valve stenosisD001024EFO_0000266—————44
Alzheimer diseaseD000544EFO_0000249F03————44
Critical illnessD016638——————33
Intracranial arteriosclerosisD002537EFO_1000860I67.2————33
Myofascial pain syndromesD009209EFO_1001054—————33
Show 332 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameEnoblituzumab
INNenoblituzumab
Description
Enoblituzumab is a monoclonal antibody designed for the treatment of cancer. Formerly known as MGA271, the drug is a humanized IgG1κ monoclonal antibody recognizing human B7-H3, a member of the B7 family of immune regulators.
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL3545373
ChEBI ID—
PubChem CID—
DrugBank—
UNII IDM6030H73N9 (ChemIDplus, GSRS)
Target
Agency Approved
CD276
CD276
Organism
Homo sapiens
Gene name
CD276
Gene synonyms
B7H3
NCBI Gene ID
Protein name
CD276 antigen
Protein synonyms
4Ig-B7-H3, B7 homolog 3, B7-H3, CD276, Costimulatory molecule
Uniprot ID
Mouse ortholog
Cd276 (102657)
CD276 antigen (Q8VE98)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Leqvio – Novartis
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Increlex – Eton Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 2,060,458 documents
View more details
Safety
Black-box Warning
Black-box warning for: 2-oak mix, red/white pollen 3-oak mix, black/blackjack/post pollen 3-ragweed mix, giant/short/western pollen 4-pine mix, austrian/loblolly/scotch/w..., Center-al - acacia longifolia pollen center-al - acer negundo pollen center-al - acer saccharum pollen center-al - agrostis gigantea center-al - al..., Xeomin
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,145 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use